SC
BBOT

Sculptor Capital’s BridgeBio Oncology BBOT Stock Holding History

Sculptor Capital’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-800,000
Closed -$8.5M – 413
2025
Q2 		$8.5M Hold
800,000
– – 0.12% 139
2025
Q1 		$9.04M Buy
800,000
+95,000
+13% +$1.02M 0.17% 108
2024
Q4 		$7.4M Hold
705,000
– – 0.1% 135
2024
Q3 		$7.37M Hold
705,000
– – 0.12% 117
2024
Q2 		$7.21M Hold
705,000
– – 0.14% 101
2024
Q1 		$7.33M Buy
+705,000
New +$7.3M 0.14% 89

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Sculptor Capital's BBOT Position: Q3 2025 in Review

Sculptor Capital sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 800,000 shares — an estimated $8.5M sold.

Sculptor Capital first reported a position in BBOT in Q1 2024 and held it in 6 quarters. The position peaked at $9.04M in Q1 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • Sculptor Capital reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • Sculptor Capital sold 800,000 BridgeBio Oncology shares in Q3 2025, an estimated $8.5M.
  • Sculptor Capital first reported a position in BridgeBio Oncology in Q1 2024 and held it in 6 quarters.
  • Sculptor Capital's BridgeBio Oncology position peaked at $9.04M in Q1 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Sculptor Capital's 13F filing for Q3 2025, filed 14 Nov 2025.